Division of Drug Information Services, The University of Iowa College of Pharmacy, Iowa City, IA 52242-4710, USA.
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:203-12. doi: 10.1002/pds.2315.
To systematically review published studies for algorithms that identified lymphoma as a health outcome of interest in administrative or claims data and examined the validity of the algorithm to identify lymphoma cases.
A systematic literature search was executed using PubMed and the Iowa Drug Information Service database. Two investigators reviewed search results to identify studies using administrative or claims databases from the USA or Canada that both reported and validated an algorithm to identify lymphoma.
The search identified 713 unique citations with 402 eliminated by an initial screen of the article abstract. The remaining 311 resulted in one study that identified and validated an algorithm. Ten other studies reported algorithms but were not validated. The validated study reported four possible algorithms that had a specificity (> 99%), but the algorithm using two diagnostic codes recorded within 2 months had the best positive predictive value (PPV = 62.83%) and a sensitivity (79.81%). The most comprehensive algorithm required multiple diagnostic codes 2 months apart or diagnostic, and procedure codes on the same day had the greatest sensitivity (88.31%) and a PPV = 56.69%. The algorithm that required only a single diagnostic or procedure code had the worst PPV (34.72%).
The International Classification of Disease, Ninth Revision diagnostic, clinical procedure, and complication codes for lymphoma can identify incident hematologic malignancies and solid tumors with high specificity but with relatively low to moderate sensitivity and PPVs. When diagnostic and procedure codes were required on the same visit or multiple codes between visits, then PPV was increased. Relying on a single registry to confirm true positive cases is also not sufficient.
系统回顾已发表的研究,以确定在行政或理赔数据中识别淋巴瘤作为感兴趣的健康结果的算法,并评估该算法识别淋巴瘤病例的有效性。
使用 PubMed 和爱荷华药物信息服务数据库进行了系统的文献检索。两名研究人员审查了检索结果,以确定使用来自美国或加拿大的行政或理赔数据库报告并验证用于识别淋巴瘤的算法的研究。
搜索共确定了 713 条独特的引文,其中 402 条通过文章摘要的初步筛选被排除。剩下的 311 条导致一项研究确定并验证了一种算法。另外 10 项研究报告了算法,但未进行验证。经过验证的研究报告了四种可能的算法,特异性均大于 99%,但使用在 2 个月内记录的两个诊断代码的算法具有最佳的阳性预测值(PPV = 62.83%)和敏感性(79.81%)。最全面的算法需要相隔 2 个月的多个诊断代码或诊断代码和程序代码同一天的代码具有最高的敏感性(88.31%)和 PPV = 56.69%。仅需要单个诊断或程序代码的算法的 PPV 最差(34.72%)。
国际疾病分类,第九版诊断,临床程序和淋巴瘤的并发症代码可以识别出具有高特异性的新发血液恶性肿瘤和实体瘤,但敏感性和 PPV 相对较低至中等。当诊断和程序代码在同一就诊时或多次就诊时需要时,PPV 会增加。仅依靠单个登记册来确认真正的阳性病例也是不够的。